Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Ovarian Cancer Diagnostics Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_
The ovarian cancer diagnostics market size has exhibited robust growth over recent years. It is anticipated to expand from $2.9 billion in 2025 to $3.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The observed growth in the past can be attributed to several factors including an increased incidence of ovarian cancer, heightened awareness surrounding women’s health concerns, the development of diagnostic laboratory infrastructure, a rise in the adoption of imaging and biopsy procedures, and the widespread availability of cancer screening programs._x000D_
_x000D_
The ovarian cancer diagnostics market is projected to experience robust expansion over the coming years. Its valuation is set to reach $4.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is primarily driven by heightened investments in precision oncology, an escalating need for the early identification of cancer, the proliferation of AI-powered diagnostic platforms, a growing emphasis on tailored treatment strategies, and increased research funding allocated to women’s cancers. Key developments expected in this period include the wider acceptance of diagnostic tests based on biomarkers, a greater utilization of sophisticated imaging techniques, the increasing incorporation of AI in cancer detection, the rollout of more early screening initiatives, and a sharpened focus on individualized oncology diagnostics._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Ovarian Cancer Diagnostics Market Growth Drivers: What’s Behind The Acceleration?#_x000D_
The rising occurrence of gynecological cancer is anticipated to propel the growth of the ovarian cancer diagnosis market moving forward. Gynecologic cancer refers to any cancer that begins in a woman’s reproductive organs. Ovarian cancer diagnosis drugs help decrease the prevalence of gynecological cancer by treating and managing the disease, preventing its recurrence, and improving patient outcomes through various therapies. For instance, in October 2025, according to Cancer Australia, an Australia-based government agency, about 6,963 new cases of gynecological cancer were diagnosed in Australia in 2024. Therefore, the high prevalence of gynecological cancer is driving the growth of the ovarian cancer diagnosis market._x000D_
_x000D_
#Ovarian Cancer Diagnostics Market Segment Analysis And Revenue Potential#_x000D_
The ovarian cancer diagnostics market covered in this report is segmented – _x000D_
_x000D_
1) By Product Type: Instruments, Kits, Reagents_x000D_
2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types_x000D_
3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor_x000D_
4) By End User: Cancer Diagnostic Centers, Hospital Laboratories_x000D_
_x000D_
Subsegments:_x000D_
1) By Instruments: Imaging Systems, Biopsy Devices, Molecular Diagnostic Instruments _x000D_
2) By Kits: Diagnostic Test Kits, Screening Kits _x000D_
3) By Reagents: Antibodies, Enzymes, Assay Reagents _x000D_
_x000D_
#Ovarian Cancer Diagnostics Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_
Leading companies active in the ovarian cancer diagnostics market are establishing alliances to create novel products and bolster their market presence. These cooperative ventures and partnerships within the ovarian cancer diagnostics market enhance efforts in research, development, and commercialization by utilizing the specialized knowledge, assets, and networks of multiple organizations. For example, in August 2023, ImmunoGen Inc., a US-based biotechnology company, collaborated with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, for the development and commercialization of ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen is slated to receive upfront and milestone payments, along with double-digit royalties, while Takeda obtains exclusive rights to develop and commercialize ELAHERE in Japan, reaffirming the commitment to deliver this biomarker-directed ADC to patients with Folate Receptor Alpha (FRα)-Positive, Platinum-Resistant Ovarian Cancer in the Japanese market. This alliance assists in addressing an unmet need for individuals with platinum-resistant ovarian cancer and emphasizes a shared dedication to progressing cancer treatment options worldwide._x000D_
_x000D_
#Ovarian Cancer Diagnostics Market Industry Leaders And Competitive Landscape#_x000D_
Major companies operating in the ovarian cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc _x000D_
_x000D_
#View The Full Ovarian Cancer Diagnostics Market Report:#_x000D_
_x000D_
#Ovarian Cancer Diagnostics Market Regional Analysis And Leading Geography#_x000D_
North America was the largest region in the ovarian cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.